A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-08-10
Adverse events
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-30 (study day 36); relationship: N
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 71); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 73); relationship: N
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-11-18 (study day 85); relationship: not assessed
Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 116); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-29 (study day 126); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-06 (study day 134); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 141); relationship: not assessed
Data queries
No data queries.